Get the Stockscreener App
1.01
4.13%
-0.03
Ocugen Inc stock is traded at $1.01, with a volume of 2.56M.
It is down -4.13% in the last 24 hours and down -8.52% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
2.56M
Relative Volume:
0.47
Market Cap:
$294.95M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.7407
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-13.30%
1M Performance:
-8.52%
6M Performance:
+40.44%
1Y Performance:
-45.51%
1-Day Range:
$0.9923
$1.06
1-Week Range:
$0.9923
$1.19
52-Week Range:
$0.515
$1.80
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.01 | 330.00M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.01 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.88 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.26 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire
Ocugen Earnings: Gene Therapy Pioneer to Report Q2 2025 Results August 1 - Stock Titan
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Building Biotech Champions: Cultivating Breakthroughs In A Dynamic Field - Life Science Leader
OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire
Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid - Investing.com
How did OCGN's Q4 earnings surprise impact its annual performance? - AInvest
After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals
Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com - Investing.com South Africa
Major Biotech Merger: Carisma and OrthoCellix Unite to Advance Revolutionary Knee Cartilage Treatment - Stock Titan
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Ocugen to Release New Investor Presentation - TipRanks
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN
OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga
Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener
Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus
FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN
Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus
Ocugen To Present at BIO International Convention 2025 - Ocugen
Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus
Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq
Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN
Ocugen signs term sheet for Korean licensing of OCU400 gene therapy - Modern Retina
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World
Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Signs License Agreement for OCU400 in Korea - TipRanks
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):